Unfolding the role of protein misfolding in neurodegenerative diseases
The DOI matches its Crossref record; 152 of the 154 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Neurodegenerative diseases, such as AD and DLB, are often characterized as diseases of protein aggregation (30–33).”
From APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia (2021) · cites this paper as [30]
In the citing paper
“Importantly, most of these age-related primary neurodegenerative diseases involve disorders of protein processing and aggregation.”
From Glymphatic failure as a final common pathway to dementia (2020) · cites this paper as [59]
In the citing paper
“The hallmark feature of these proteinopathies are the fibrillary aggregates of misfolded or hyperphosphorylated proteins (59).”
From Glymphatic failure as a final common pathway to dementia (2020) · cites this paper as [59]
Citations
Cites
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382 · cited 1×
“Soluble multimeric Alzheimer β(1-40) preamyloid complexes in dilute solution.”
BackgroundMACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · cited 1×
“Soluble multimeric Alzheimer β(1-40) preamyloid complexes in dilute solution.”
BackgroundRosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062 · cited 1×
“Soluble multimeric Alzheimer β(1-40) preamyloid complexes in dilute solution.”
BackgroundGlenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“Soluble multimeric Alzheimer β(1-40) preamyloid complexes in dilute solution.”
BackgroundTerry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397 · cited 1×
“Soluble multimeric Alzheimer β(1-40) preamyloid complexes in dilute solution.”
BackgroundWalsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143 · cited 1×
“Soluble multimeric Alzheimer β(1-40) preamyloid complexes in dilute solution.”
Background
Cited by
Items 501–600 of 1,001
Elgersma, R. C., Rutters-Meijneke, T., Posthuma, G., Rijkers, D. T. S., & Liskamp, R. M. J. (2006) · Chemistry - A European Journal · doi:10.1002/chem.200501374 · Cited by 45
How the binding and degrading capabilities of insulin degrading enzyme are affected by ubiquitin
Grasso, G., Rizzarelli, E., & Spoto, G. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2008.04.011 · Cited by 43
Shal, B., Khan, A., Khan, A. U., Ullah, R., Ali, G., Islam, S. U., Haq, I. U., Ali, H., Seo, E. K., & Khan, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126603 · Cited by 46
“The progress of AD is linked to the conformational changes and misfolding of Aβ peptides, leading to aggregation into oligomers and mature fibrils [53].”
BackgroundThe entrancing role of dietary polyphenols against the most frequent aging‐associated diseases
Shah, M. A., Faheem, H. I., Hamid, A., Yousaf, R., Haris, M., Saleem, U., Shah, G. M., Alhasani, R. H., Althobaiti, N. A., Alsharif, I., et al. (2023) · Medicinal Research Reviews · doi:10.1002/med.21985 · Cited by 45
“91 Deficiency of dopamine ‐ releasing neurons in turn leads to the metabolism of the remaining dopamine neurons, thus further worsening the situation and also increases the production of oxy free radicals responsible for the progression of the disease.”
BackgroundLi, L., Jin, Z., Tan, H., Xu, Q., Peng, T., & He, L. (2016) · Brain Research · doi:10.1016/j.brainres.2016.03.027 · Cited by 47
“Mutant Htt containing polyglutamine (polyQ) repeats with over 36 glutamines causes protein aggregation and formation of inclusion bodies in the cytoplasm and nucleus, which is toxic to cells (Davies et al., 1997; Imarisio et al., 2008; Ross, 1997; Ross and Poirier, 2004; Soto, 2003).”
BackgroundER Stress and Neurodegenerative Disease: A Cause or Effect Relationship?
Cabral‐Miranda, F., & Hetz, C. A. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_52 · Cited by 51
Mechanistic Insights into the Co-Aggregation of Aβ and hIAPP: An All-Atom Molecular Dynamic Study
Li, X., Lao, Z., Zou, Y. F., Dong, X., Li, L., & Wei, G. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.0c11132 · Cited by 42
NALP3 inflammasome activation in protein misfolding diseases
Shi, F., Kouadir, M., & Yang, Y. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.05.011 · Cited by 44
Unfolded Protein Response Signaling in Liver Disorders: A 2023 Updated Review
Shreya, S., Grosset, C. F., & Jain, B. P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814066 · Cited by 46
“Many neurodegenerative diseases like Parkinson’s disease and Alzheimer’s disease are characterized by the deposition of misfolded proteins in neurons [9].”
BackgroundCrespo, I., Roomp, K., Jurkowski, W., Kitano, H., & del Sol, A. (2012) · BMC Systems Biology · doi:10.1186/1752-0509-6-132 · Cited by 41
“Several hypotheses have been put forward to explain prion disease pathogenesis, such as Prion loss-of-function, Prion gain-of-toxic function, endoplasmatic reticulum stress, activation of autophagy and/or apoptotic death pathways, and chronic brain inflammation induced by misfolded protein and neuronal injury [2], but…”
BackgroundAltered Prion Protein Expression Pattern in CSF as a Biomarker for Creutzfeldt-Jakob Disease
Torres, M., Cartier, L., Matamala, J. M., Hernández, N., Woehlbier, U., & Hetz, C. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036159 · Cited by 41
“Protein misfolding is a common hallmark of several neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), as well as Prionrelated disorders (PrDs), among other pathologies [1].”
BackgroundSeo, B.-R., Lee, S.-J., Cho, K. S., Yoon, Y. H., & Koh, J. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.09.006 · Cited by 44
“A rapidly growing body of evidence indicates that abnormalities in autophagy play a central role in the pathogenesis of diverse neurodegenerative disorders including AD and Parkinson’s disease (Soto, 2003; Soto and Estrada, 2008).”
Structural studies on the mechanism of protein aggregation in age related neurodegenerative diseases
Eftekharzadeh, B., Hyman, B. T., & Wegmann, S. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.03.001 · Cited by 50
García, V. M. G., Nillegoda, N. B., Bukau, B., & Morano, K. A. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-01-0070 · Cited by 41
“Misfolded proteins or amyloid aggregates contribute to the development or progression of neurodegenerative disorders: Alzheimer, Huntington, and Parkinson diseases are all fundamentally diseases of protein misfolding (Soto, 2003; Broadley and Hartl, 2009).”
BackgroundHierarchical self-assembly of a β-amyloid peptide derivative
Qin, S., Pei, Y., Liu, X., Zhuo, R., & Zhang, X. (2012) · Journal of Materials Chemistry B · doi:10.1039/c2tb00105e · Cited by 41
CNS Redox Homeostasis and Dysfunction in Neurodegenerative Diseases
Goldsteins, G., Hakosalo, V., Jaronen, M., Keuters, M. H., Lehtonen, Š., & Koıstınaho, J. (2022) · Antioxidants · doi:10.3390/antiox11020405 · Cited by 44
“Intracellular protein accumulation is a hallmark of many NDs, including AD, PD, ALS, and HD [52].”
BackgroundPrion‐like protein aggregates exploit the RHO GTPase to cofilin‐1 signaling pathway to enter cells
Zhong, Z., Grasso, L., Sibilla, C., Stevens, T. J., Barry, N. P., & Bertolotti, A. (2018) · The EMBO Journal · doi:10.15252/embj.201797822 · Cited by 46
“…deposition of proteins of abnormal conformation is at the origin of a broad range of human age-related diseases including the devastating neurodegenerative diseases Alzheimer’s (AD), Parkinson’s (PD), Huntington’s (HD), amyotrophic lateral sclerosis (ALS), dementia and prion diseases (Soto, 2003).”
Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer’s Disease
Vander Zanden, C. M., & Chi, E. Y. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.10.024 · Cited by 41
Pradeepkiran, J. A., & Reddy, P. H. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166162 · Cited by 41
Zhang, S., Li, J., Xu, Q., Xia, W., Tao, Y., Shi, C., Li, D., Xiang, S., & Liu, C. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c10854 · Cited by 47
Free radical theory of autoimmunity
Kannan, S. (2006) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-3-22 · Cited by 41
An Azobenzene Photoswitch Sheds Light on Turn Nucleation in Amyloid-β Self-Assembly
Doran, T. M., Anderson, E. A., Latchney, S. E., Opanashuk, L. A., & Nilsson, B. L. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn2001188 · Cited by 42
Five Questions (with their Answers) on ER ‐Associated Degradation
Pisoni, G. B., & Molinari, M. (2016) · Traffic · doi:10.1111/tra.12373 · Cited by 42
“Such delays may result from inherited or sporadic mutations of the polypeptide sequence (22,38), from non-stoichiometric synthesis of multimeric complex’s subunits, for example, due to the gene duplications found in some cancer types (39) or from perturbations in the folding environment.”
BackgroundA tailored mouse model of CLN2 disease: A nonsense mutant for testing personalized therapies
Geraets, R. D., Langin, L. M., Cain, J. T., Parker, C., Beraldi, R., Kovács, A., Weimer, J. M., & Pearce, D. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176526 · Cited by 41
Suppression of MAPK11 or HIPK3 reduces mutant Huntingtin levels in Huntington's disease models
Yu, M., Fu, Y., Liang, Y., Song, H., Yao, Y., Wu, P., Yao, Y., Pan, Y., Wen, X., Ma, L., et al. (2017) · Cell Research · doi:10.1038/cr.2017.113 · Cited by 41
Dong, X., Qiao, Q., Qian, Z., & Wei, G. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.03.006 · Cited by 39
Murugan, N. A., Nordberg, A. K., & Ågren, H. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00340 · Cited by 44
Levy, M., Porat, Y., Bacharach, E., Shalev, D. E., & Gazit, E. (2008) · Biochemistry · doi:10.1021/bi800043d · Cited by 39
Switch‐peptides as folding precursors in self‐assembling peptides and amyloid fibrillogenesis
Tuchscherer, G., Chandravarkar, A., Camus, M., Bérard, J., Murat, K., Schmid, A. W., Mimna, R., Lashuel, H. A., & Mutter, M. (2007) · Biopolymers · doi:10.1002/bip.20663 · Cited by 44
Directing the secondary structure of polypeptides at will: from helices to amyloids and back again?
Pagel, K., Vagt, T., & Koksch, B. (2005) · Organic & Biomolecular Chemistry · doi:10.1039/b510098d · Cited by 40
Mutter, M., Chandravarkar, A., Boyat, C., Lopez, J., Santos, S. D., Mandal, B., Mimna, R., Murat, K., Patiny, L., Saucède, L., et al. (2004) · Angewandte Chemie · doi:10.1002/ange.200454045 · Cited by 39
Li, D., & Liu, C. (2023) · Structure · doi:10.1016/j.str.2023.08.006 · Cited by 39
Navigating the intersection: Diabetes and Alzheimer's intertwined relationship
Kale, M. B., Bhondge, H. M., Wankhede, N. L., Shende, P. V., Thanekar, R., Aglawe, M. M., Rahangdale, S. R., Taksande, B. G., Pandit, S. B., Upaganlawar, A. B., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102415 · Cited by 39
Wu, J., Li, C.-S., Huang, W., Zhou, S.-Y., Zhao, L., Li, T., Li, M., Zhang, M.-X., Qiao, C.-M., Zhao, W.-J., et al. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.04.001 · Cited by 43
Quality Control Compartments Coming of Age
Ben‐Gedalya, T., & Cohen, E. (2012) · Traffic · doi:10.1111/j.1600-0854.2012.01330.x · Cited by 40
“Accordingly, aggregate deposition sites are the hallmark features of various neurodegenerative diseases (9,12,18).”
BackgroundElgersma, R. C., Mulder, G. E., Kruijtzer, J. A. W., Posthuma, G., Rijkers, D. T. S., & Liskamp, R. M. J. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.01.042 · Cited by 38
The Roles of Cellular and Organismal Aging in the Development of Late-Onset Maladies
Marques, F. C., Volovik, Y., & Cohen, E. (2014) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040508 · Cited by 41
Nanochaperones Mediated Delivery of Insulin
Li, C., Liu, X., Zhang, Y., Lv, J., Huang, F., Wu, G., Liu, Y., Ma, R., An, Y., & Shi, L. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b04966 · Cited by 38
Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases
Akter, R., Rahman, H., Behl, T., Chowdhury, M. A. R., Manirujjaman, M., Bulbul, I. J., Elshenawy, S. E., Ţiţ, D. M., & BUNGAU, S. G. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210218084444 · Cited by 44
Polymeric Ligands with Specificity for Aggregated Prion Proteins
Lane, A., Stanley, C. J., Dealler, S., & Wilson, S. M. (2003) · Clinical Chemistry · doi:10.1373/49.10.1774 · Cited by 38
Rana, P. S., Ignatz-Hoover, J. J., & Driscoll, J. J. (2023) · Cancers · doi:10.3390/cancers15235632 · Cited by 41
“Deregulation of proteasome activity has been reported during neurodegenerative processes, i.e., the deposition of protein aggregates within the cell [115,116].”
BackgroundSin, O., & Nollen, E. A. A. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1985-0 · Cited by 46
Tinker, C. L., Mayes, J., Allsop, D., & Kolosov, O. (2014) · Scientific Reports · doi:10.1038/srep04004 · Cited by 41
“Imaging real-time aggregation of amyloid beta protein (1-42) by atomic force microscopy.”
BackgroundMethodInfluentialJia, Y., Jin, W., Xiao, Y., Dong, Y., Wang, T., Fan, M., Xu, J., Meng, N., Li, L., & Lv, P. (2015) · Cellular & Molecular Biology Letters · doi:10.1515/cmble-2015-0027 · Cited by 38
Prion-like characteristics of the bacterial protein Microcin E492
Shahnawaz, M., Park, K., Mukherjee, A., Díaz‐Espinoza, R., & Soto, C. A. (2017) · Scientific Reports · doi:10.1038/srep45720 · Cited by 41
“Mcc possesses several hallmark features of authentic prions, namely: (1) The protein exists in two structurally and functionally different forms, Mcca and Mccia; (2) Mccia is the prion form that adopts a β -sheet-rich amyloid-like conformation that is formed by a seeding/nucleation mechanism; (3) Like PrPSc, Mccia is…”
BackgroundSelf-citationSolvation-Guided Design of Fluorescent Probes for Discrimination of Amyloids
Cao, K., Elbel, K. M., Cifelli, J. L., Cirera, J., Sigurdson, C. J., Paesani, F., Theodorakis, E. A., & Yang, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-25131-2 · Cited by 38
Advanced Simulation of Droplet Microfluidics
Grimmer, A., Hamidović, M., Haselmayr, W., & Wille, R. (2019) · ACM Journal on Emerging Technologies in Computing Systems · doi:10.1145/3313867 · Cited by 37
“This microfluidic network is developed to screen drug compounds that inhibit the tau-peptide aggregation, which is a phenomenon related to neurodegenerative disorders such as Alzheimer’s disease [25].”
BackgroundCase, A. W., Ni, J., Yeh, L.-A., & Stein, R. L. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.09.047 · Cited by 37
Grunwald, M. E., & Kaplan, J. M. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00274-0 · Cited by 41
Molecular Investigations of Protein Aggregation in the Pathogenesis of Amyotrophic Lateral Sclerosis
Duranti, E., & Villa, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010704 · Cited by 43
“From a pathophysiological point of view, different pathologies are distinguished by the synthesis of aberrant proteins that can undergo conformational changes and acquire a toxic function or block their original biological activity [20].”
BackgroundMapping out the multistage fibrillation of glucagon
Ghodke, S. D., Nielsen, S. B., Christiansen, G., Hjuler, H. A., Flink, J. M., & Otzen, D. E. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08465.x · Cited by 36
How Implementation of Systems Biology into Clinical Trials Accelerates Understanding of Diseases
Bielekova, B., Vodovotz, Y., An, G. C., & Hallenbeck, J. M. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00102 · Cited by 42
“, inflammation, mitochondrial dysfunction, oxidative stress, endoplasmic reticulum (ER) stress, excitotoxicity, DNA damage, autophagy, and tissue remodeling) are observed in the target tissue of patients with varied polygenic diseases (1, 2), including different stages of MS (3).”
BackgroundShah, S. Z. A., Zhao, D., Hussain, T. A., & Yang, L. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00120 · Cited by 37
“Long-term and severe ER stress dysregulates Ca2+ homeostasis and causes cytotoxic, synaptotoxic and behavioral changes (Mukherjee and Soto, 2011; Soto and Satani, 2011).”
BackgroundExploring the multifaceted roles of heat shock protein B8 (HSPB8) in diseases
Li, F., Xiao, H., Hu, Z., Zhou, F., & Yang, B. (2018) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2018.03.003 · Cited by 38
Peptide Self-Assembled Nanostructures: From Models to Therapeutic Peptides
Gatto, E., Toniolo, C., & Venanzi, M. (2022) · Nanomaterials · doi:10.3390/nano12030466 · Cited by 40
“Soto demonstrated that incorporation of βbreaker elements into short peptides able to target amyloidogenic protein definitely hinder amyloid formation [81].”
BackgroundStravalaci, M., Beeg, M., Salmona, M., & Gobbi, M. (2010) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2010.10.038 · Cited by 36
“Introduction A broad range of human diseases, known as protein misfolding iseases, are characterized by the conversion of specific proteins or eptides to conformations with high propensity to aggregate, form- ng amyloid fibrils (Chiti and Dobson, 2006; Soto, 2003).”
BackgroundDhenain, M., Delatour, B., Walczak, C., & Volk, A. (2006) · Magnetic Resonance in Medicine · doi:10.1002/mrm.20810 · Cited by 36
“(2) The spots were localized in areas that are known to display amyloid deposits, such as the subiculum, the hippocampus, and the cortex.”
BackgroundTherapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
Liu, J., Ting, J. P., Al-Azzam, S., Ding, Y., & Afshar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062805 · Cited by 40
Oxidative Stress-Induced Misfolding and Inclusion Formation of Nrf2 and Keap1
Ngo, V., Karunatilleke, N. C., Brickenden, A. M., Choy, W., & Duennwald, M. L. (2022) · Antioxidants · doi:10.3390/antiox11020243 · Cited by 37
“The question remains then, if oxidized Nrf2 and Keap1 inclusions are reversible by thioredoxinmediated disulfide bond reduction and protein refolding by molecular chaperones, and to what extent are these inclusions tolerated before it becomes irreversible and toxic? This question is particularly important in the conte…”
BackgroundChiral Engineered Biomaterials: New Frontiers in Cellular Fate Regulation for Regenerative Medicine
Wang, Y., Zhang, X., Xie, D., Chen, C., Huang, Z., & Li, Z. A. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202419610 · Cited by 40
Torres, M., Matamala, J. M., Duran-Aniotz, C. A., Cornejo, V. H., Foley, A., & Hetz, C. A. (2014) · Virus Research · doi:10.1016/j.virusres.2014.12.018 · Cited by 43
“PMDs include several cerebral and systemic myloid diseases such as Alzheimer’s disease (AD), Parkinson’s isease, Huntington’s disease, type-2 diabetes and transmissible pongiform encephalopathies or Prion-related Diseases (PrD) Dobson, 2002; Soto, 2003).”
BackgroundToxic effects of different charged metal ions on the target—Bovine serum albumin
Zhang, H., Liu, R., Chi, Z., & Gao, C. (2010) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2010.11.021 · Cited by 35
Role of the unfolded protein response in the pathogenesis of Parkinson’s disease
Varma, D. V. S. N. S., & Sen, D. (2015) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2015-2012 · Cited by 37
“Parkinson's disease (PD) is a type of protein misfolding disorder (Soto 2003) which impairs movement and control and thus it is often termed as a 'movement disorder'.”
BackgroundGene therapy to target ER stress in brain diseases
Valenzuela, V., Martínez, G., Duran-Aniotz, C. A., & Hetz, C. A. (2016) · Brain Research · doi:10.1016/j.brainres.2016.04.064 · Cited by 40
“…a common feature of most common neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Alzheimer's disease (AD), Huntington´s disease, retinitis pigmentosa, among other pathologies that are classified as protein misfolding disorders (PMDs) (Soto, 2003).”
BackgroundDelivery systems for theranostics in neurodegenerative diseases
Li, Y., Liu, R., Ji, W., Li, Y., Liu, L., & Zhang, X. (2018) · Nano Research · doi:10.1007/s12274-018-2067-z · Cited by 36
“Neuron degeneration can impair movement or memory, which has a debilitating effect on the patient’s quality of life [9].”
BackgroundLee, J., Xu, Y., Zhang, T., Cui, L., Saidi, L., & Ye, Y. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003660 · Cited by 32
“endosome (LE) (2) for translocation across the membrane (3).”
BackgroundFanni, A. M., Monge, F. A., Lin, C.-Y., Thapa, A., Bhaskar, K., Whitten, D. G., & Chi, E. Y. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00719 · Cited by 40
Taran, A., Belikova, L. D., Lagarkova, M. A., & Alieva, I. B. (2020) · Cells · doi:10.3390/cells9061514 · Cited by 40
“Together these data indicate that Huntington’s disease is a classic example of proteinopathies [119].”
BackgroundMelatonin Can Modulate Neurodegenerative Diseases by Regulating Endoplasmic Reticulum Stress
Yoo, Y., & Joo, S. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032381 · Cited by 36
“Common causes of neurodegenerative diseases include the accumulation and deposition of misfolded proteins that affect neuronal connectivity, cell death, and faulty cell signaling [4,5].”
Popiel, H. A., Takeuchi, T., Burke, J. R., Strittmatter, W. J., Toda, T., Wada, K., & Nagai, Y. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0184-7 · Cited by 35
Atg4b-Dependent Autophagic Flux Alleviates Huntington’s Disease Progression
Proenca, C. C., Stoehr, N., Bernhard, M., Seger, S., Genoud, C., Roscic, A., Paganetti, P., Liu, S., Murphy, L. O., Kuhn, R. R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068357 · Cited by 37
“formation of inclusion bodies; and evidence points to a protective role for degradation of protein aggregation [35,36].”
BackgroundNeurodegeneration Caused by Proteins with an Aberrant Carboxyl-Terminus
Vidal, R., Delisle, M. B., & Ghetti, B. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.8.787 · Cited by 36
“These structures are commonly short, thin, fibrillar species that are thought to assemble into mature fibrils, perhaps by lateral association (4, 5).”
BackgroundFeng, S., & Yan, Y. (2007) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.21744 · Cited by 39
Exploring the Basis of [PIN+] Variant Differences in [PSI+] Induction
Sharma, J., & Liebman, S. W. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.06.006 · Cited by 34
“For example, Alzheimer's disease is associated with Aβ (amyloid beta-protein) amyloid, Huntington's disease is associated with mutant huntingtin amyloid, Parkinson's disease is associated with α-synuclein amyloid, and type II diabetes is associated with insulin amyloid precursor peptide [6].”
BackgroundMitochondrial Respiration Is Impaired during Late-Stage Hamster Prion Infection
Faris, R., Moore, R. A., Ward, A., Sturdevant, D. E., & Priola, S. A. (2017) · Journal of Virology · doi:10.1128/jvi.00524-17 · Cited by 35
“Some studies have shown that PrPSc can be toxic to neuronal cells and trigger endoplasmic reticulum (ER) stress ultimately followed by apoptosis (2).”
BackgroundAtomic Force Microscopy in Probing Tumor Physics for Nanomedicine
Li, M., Xi, N., Wang, Y., & Liu, L. (2018) · IEEE Transactions on Nanotechnology · doi:10.1109/tnano.2018.2882383 · Cited by 35
“On the contrary, protein misfolding, which is an important cause of diverse neurodegenerative diseases, yields abnormal mechanical properties of the proteins [227], [228].”
BackgroundDong, X., Tang, Y., Zhan, C., & Wei, G. (2020) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2020.105024 · Cited by 35
Microbiota-Gut-Brain Communication in the SARS-CoV-2 Infection
Manosso, L. M., Arent, C. O., Borba, L. A., Ceretta, L. B., Quevedo, J., & Réus, G. Z. (2021) · Cells · doi:10.3390/cells10081993 · Cited by 38
Hughes, S., van Dop, M., Kolsters, N., van de Klashorst, D., Pogosova, A., & Rijs, A. M. (2022) · Pharmaceuticals · doi:10.3390/ph15050512 · Cited by 35
Protein and Gene Delivery Systems for Neurodegenerative Disorders: Where Do We Stand Today?
Siafaka, P. I., Okur, M. E., Dilsiz, P., Çağlar, E. Ş., Özgenç, E., Gündoğdu, E., Köprülü, R. E. P., Karantas, I. D., & Okur, N. Ü. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112425 · Cited by 35
“tic impairment, and brain damage, which are symptoms commonly observed in a wide range of neurodegenerative diseases [26,27].”
BackgroundSystematic identification of structure-specific protein–protein interactions
(2024) · doi:10.1038/s44320-024-00037-6 · Cited by 34
“…s disease (AD), and Huntington ’ s disease, disease-associated proteins (e.g., alpha-synuclein (aSyn), amyloid-β , tau, or huntingtin) aggregate into β -sheet-rich structures that are thought to be toxic to cells (Soto, 2003; Goedert, 2015; Bates, 2003; Taylor et al, 2002; Ross and Poirier, 2004).”
Liquid-liquid phase separation in Alzheimer’s disease
Fu, Q., Zhang, B., Chen, X., & Chu, L. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-023-02407-3 · Cited by 33
“It is well-known that the pathological aggregation of Aβ, like tau, is also the hallmark of AD [64, 124, 125].”
A Data-Driven Evolutionary Algorithm for Mapping Multibasin Protein Energy Landscapes
Clausen, R., & Shehu, A. (2015) · Journal of Computational Biology · doi:10.1089/cmb.2015.0107 · Cited by 34
“In some proteinopathies, loss of protein function can be explained by loss of a crucial stable structure (Soto, 2003, 2008).”
Translating endoplasmic reticulum biology into the clinic: a role for ER-targeted natural products?
Pereira, D. M., Valentão, P., Correia‐da‐Silva, G., Teixeira, N. A. A., & Andrade, P. B. (2015) · Natural Product Reports · doi:10.1039/c4np00102h · Cited by 37
Wang, T., Xie, X.-X., Ji, M., Wang, S., Zha, J., Zhou, W.-W., Yu, X., Chen, W., Ma, S., Xi, Z.-Y., et al. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.02.015 · Cited by 35
EPR of site-directed spin-labeled proteins: A powerful tool to study structural flexibility
García‐Rubio, I. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108323 · Cited by 33
Different Aggregation Pathways and Structures for Aβ40 and Aβ42 Peptides
Wang, L., Eom, K., & Kwon, T. (2021) · Biomolecules · doi:10.3390/biom11020198 · Cited by 36
“…exist in the form of a macromolecular structure, referred to as amyloid structure, that is locally deposited in organs or tissues because of the aggregation of denatured or misfolded proteins [4,5], and this amyloid structure is a very stable substance and not easily degraded once formed [4,6].”
Impairment of microtubule system increases α-synuclein aggregation and toxicity
Kim, M., Jung, W.-S., Lee, I., Bhak, G., Paik, S. R., & Hahn, J. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.11.020 · Cited by 33
Docking Ligands on Protein Surfaces: The Case Study of Prion Protein
Kranjc, A., Bongarzone, S., Rossetti, G., Biarnés, X., Cavalli, A., Bolognesi, M. L., Roberti, M., Legname, G., & Carloni, P. (2009) · Journal of Chemical Theory and Computation · doi:10.1021/ct900257t · Cited by 33
Mai, C. T., Le, Q. G., Ishiwata‐Kimata, Y., Takagi, H., Kohno, K., & Kimata, Y. (2018) · FEMS Yeast Research · doi:10.1093/femsyr/foy016 · Cited by 33
Chemistry in Living Cells: Detection of Active Proteasomes by a Two‐Step Labeling Strategy
Ovaa, H., van Swieten, P. F., Kessler, B. M., Leeuwenburgh, M. A., Fiebiger, E., van den Nieuwendijk, A. M. C. H., Galardy, P. J., van der Marel, G. A., Ploegh, H. L., & Overkleeft, H. S. (2003) · Angewandte Chemie · doi:10.1002/ange.200351314 · Cited by 33
Proteolytic Antibody Light Chains Alter β-Amyloid Aggregation and Prevent Cytotoxicity
Liu, R., McAllister, C., Lyubchenko, Y. L., & Sierks, M. R. (2004) · Biochemistry · doi:10.1021/bi0492354 · Cited by 35
Turn Nucleation Perturbs Amyloid β Self-Assembly and Cytotoxicity
Doran, T. M., Anderson, E. A., Latchney, S. E., Opanashuk, L. A., & Nilsson, B. L. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.01.055 · Cited by 32
Panikkanvalappil, S. R., James, M. L., Hira, S. M., Mobley, J. A., Jilling, T., Ambalavanan, N., & El‐Sayed, M. A. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b13177 · Cited by 34
Sharma, B., Kalita, S., Paul, A., Mandal, B., & Paul, S. (2016) · RSC Advances · doi:10.1039/c6ra17602j · Cited by 33
Vincenz‐Donnelly, L., Holthusen, H., Körner, R., Hansen, E. C., Presto, J., Johansson, J., Sawarkar, R., Hartl, F. U., & Hipp, M. S. (2017) · The EMBO Journal · doi:10.15252/embj.201695841 · Cited by 36
“…with neurodegeneration or systemic amyloidosis are co-translationally targeted to the ER and processed within the secretory pathway, including the Alzheimer amyloid precursor, the prion protein PrP c , the neuroserpins, and the transthyretins (Davis et al , 1999; Soto, 2003; Sorgjerd et al , 2006).”
Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease
Dansson, H. V., Stempfle, L., Egilsdóttir, H., Schliep, A., Portelius, E., Blennow, K., Zetterberg, H., Johansson, F., & Initiative, A. D. N. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00886-5 · Cited by 48
“A key pathological hallmark, required for an AD diagnosis, is the accumulation of Aβ peptides into plaques, located extracellularly, and in intracellular tangles, consisting of phosphorylated tau (p-tau) protein [6, 7].”
BackgroundThe Thermal Stress Coping Network of the Nematode Caenorhabditis elegans
Kyriakou, E., Taouktsi, E., & Syntichaki, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314907 · Cited by 33
Museth, A. K., Brorsson, A., Lundqvist, M., Tibell, L. A. E., & Jonsson, B. (2009) · Biochemistry · doi:10.1021/bi900703v · Cited by 32
Wen, L., Han, F., Shi, Y., & Li, X. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0755-2 · Cited by 38
Metadata
- Authors
- Soto, C.
- Corresponding author
- Soto, Claudio
- ORCID
- Soto, Claudio
- Venue
- Nature Reviews Neuroscience
- Published
- 2003-01
- Volume
- 4
- Issue
- 1
- Pages
- 49-60
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2007157911
- Cited by
- 1,506
- References
- 154
- Citations by year
- 2026: 45 · 2025: 70 · 2024: 75 · 2023: 73 · 2022: 95 · 2021: 88 · 2020: 107 · 2019: 80 · 2018: 86 · 2017: 107 · 2016: 92 · 2015: 75 · 2014: 67 · 2013: 45 · 2012: 57
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- protein misfolding, neurodegenerative diseases, protein aggregation, protein accumulation, neuronal apoptosis, common pathogenic mechanisms, therapeutic target
- MeSH terms
- Animals, Brain, Brain Chemistry, Humans, Protein Folding, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.